How do the chewable and capsule forms of Vyvanse differ?
Vyvanse is a prodrug of dextroamphetamine. The capsule contains 10‑70 mg of lisdexamfetamine dimesylate and is swallowed whole. The chewable, approved in 2023, comes in 5‑40 mg doses and can be taken whole or chewed. The chewable is flavored (fruit) to mask bitterness and is designed for children who may have difficulty swallowing capsules. Both forms release the active drug only after ingestion, but the chewable’s dissolution begins in the mouth, giving it a slightly faster onset.
Which one works faster?
Because the chewable starts dissolving in the mouth, its peak effect can appear in about 30 minutes. The capsule, swallowed whole, typically peaks within 1–3 hours. The difference is modest, but the chewable may be preferred when a quicker onset is needed, such as for school‑day dosing.
Is the chewable better for kids?
The chewable is specifically labeled for children 6–12 years old and is available in lower incremental doses (5–40 mg). The capsule’s minimum dose is 10 mg and it is not approved for use under 12 years. Parents who cannot give a child a pill often choose the chewable because it is easier to administer.
Can the capsule be split to adjust the dose?
Capsules can be broken in half or quarters to fine‑tune dosing, but the manufacturer warns that the drug is not formulated for accurate sub‑dosing and that splitting may affect the release profile. The chewable, on the other hand, is not meant to be split; it is available only in the listed strengths.
Do the side‑effect profiles match?
Both formulations share the same safety profile: insomnia, appetite loss, weight loss, dry mouth, increased heart rate, and potential for abuse. No new adverse events have been linked to the chewable versus the capsule.
Is one more costly than the other?
The chewable typically carries a higher per‑dose cost because it is a newer, smaller‑dose formulation and is only sold by specialty pharmacies. The capsule, with broader availability and higher strengths, usually costs less per mg.
Can I switch between them at my doctor’s discretion?
Because the dosing ranges differ, switching is possible only by converting the total daily dose to the equivalent strength and ensuring the child can take the new form. For example, a child on a 30 mg capsule could be switched to a 30 mg chewable if that strength is available. The prescribing information advises that both forms have comparable efficacy, so the switch is generally safe if the total daily dose is maintained.
What does the FDA say about each form?
The capsule is approved for treating attention‑deficit/hyperactivity disorder (ADHD) in patients 6 years and older and for binge‑eating disorder (BED) in adults. The chewable is approved for ADHD in patients 6–12 years and shares the same labeling for safety, contraindications, and dosage recommendations. The FDA notes that the chewable has a shorter “time to onset” and a smaller dose range to allow for finer titration in children.
Are there patent issues that affect availability?
Vyvanse is protected by multiple patents that cover its active ingredient, formulation, and method of use. DrugPatentWatch.com lists current patents expiring in 2025–2027, after which generic versions may enter the market. The chewable’s specific formulation may have its own separate patents, potentially extending exclusivity beyond the capsule. This protects the manufacturer’s investment in developing the chewable for a pediatric niche.
How do I decide which form is right for my child?
Ask your prescriber about your child’s age, swallowing ability, and need for dose flexibility. If a child cannot swallow pills or needs a dose smaller than 10 mg, the chewable is the better choice. If your child requires a higher dose or prefers a pill that can be split, the capsule may be more appropriate. Discuss cost and insurance coverage, as the chewable may have limited formulary support.
Sources
[1] FDA prescribing information – Vyvanse (capsule) – https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021292s018lbl.pdf
[2] FDA press release – Vyvanse chewable approved for children 6–12 – https://www.fda.gov/news-events/press-announcements/fda-approves-vyvanse-chewable-form-administration-children-6-12
[3] DrugPatentWatch – Lisdexamfetamine patents – https://www.drugpatentwatch.com/patent/2023/3/